KIND1 Loss Sensitizes Keratinocytes to UV-Induced Inflammatory Response and DNA Damage

详细信息    查看全文

• 作者：Xiaoling Zhang¹ ; ⁷ ; Suju Luo¹ ; ² ; ⁷ ; Joseph Wu¹ ; Long Zhang¹ ; ³ ; Wen-hui Wang¹ ; ⁴ ; Simone Degan¹ ; ⁵ ; Detlev Erdmann⁶ ; Russell Hall¹ ; Jennifer Y. Zhang¹ ; ^{Jennifer.zhang@duke.edu}
• 关键词：ChIP ; chromatin immunoprecipitation ; CPD ; cyclobutane pyrimidine dimers ; JNK ; c-Jun N-terminal kinase ; KS ; Kindler syndrome ; RT-PCR ; reverse transcriptase-PCR ; SCC ; squamous cell carcinoma
• 刊名：Journal of Investigative Dermatology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：137
• 期：2
• 页码：475-483
• 全文大小：4177 K
• 卷排序：137

文摘

Loss of function of KIND1, a cytoskeletal protein involved in β1-integrin function, causes Kindler syndrome, a genetic disease characterized by skin fragility, photosensitivity, and increased risk of squamous cell carcinoma. Dysregulation of β1-integrin underlies Kindler syndrome skin fragility. However, the mechanisms underlying squamous cell carcinoma susceptibility are unclear. Here, we demonstrate that gene silencing of KIND1 decreased keratinocyte proliferation and increased apoptosis in vitro and in skin grafts regenerated on mice, which was correlated with reduced cyclinB1. In addition, KIND1 loss sensitized keratinocytes to cytokine and UV-induced NF-κB and c-Jun N-terminal kinase activation and upregulation of CXCL10 and tumor necrosis factor-α. Moreover, KIND1 loss impaired DNA repair, as indicated by the increased detection of γH2AX and cyclobutane pyrimidine dimers 24 hours after UVB radiation. Genetic or pharmacological c-Jun N-terminal kinase inhibition and NF-κB inhibition markedly reduced cyclobutane pyrimidine dimers-positive cells. Further, we show that KIND1 was regulated by JunB at the transcriptional level and, like JunB, it was downregulated in human squamous cell carcinoma cells. Together, these results indicate that KIND1 is important not only for keratinocyte proliferation but also for the suppression of UV-induced inflammation and DNA damage. These latter findings support a tumor suppressor function for KIND1, and identify c-Jun N-terminal kinase and NF-κB as potential therapeutic targets for prevention of squamous cell carcinoma in patients with Kindler syndrome.